Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 2/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643425 | 0.91 | LPAR1 (0.43) | CYP2D6CYP2C19ACLYFABP4FABP3 | |
| SCHEMBL12646977 | 0.79 | PDE4B (0.45) | CYP2D6CYP2C19ACLYMAPTHTT | |
| SCHEMBL1643441 | 0.78 | P4HB (0.57) | CYP2D6CYP2C19ACLYFABP4FABP3 | |
| SCHEMBL12727689 | 0.78 | SGMS2 (0.48) | CYP2D6CYP2C19MEN1KMT2AALDH1A1 | |
| SCHEMBL16429614 | 0.78 | HNF4A (0.44) | CYP2D6CYP2C19FABP4FABP3FABP5 | |
| SCHEMBL12675962 | 0.77 | KDM4E (0.39) | MAPTHTTALDH1A1KDM4EGAA | |
| SCHEMBL29941297 | 0.76 | KDM4E (0.57) | ACLYMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL7725113 | 0.76 | KDM4E (0.57) | ACLYMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL1641884 | 0.74 | SGMS2 (0.53) | MEN1KMT2AALDH1A1CA1CA2 | |
| SCHEMBL5595331 | 0.74 | POLB (0.56) | LPAR1MAPTHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530593-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530593-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530593-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-10 | — | — | US | disclosed |
| WO-2011056432-A2 | CATALYST COMPOUNDS AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110098431-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098431-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098431-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098431-A1 | Catalyst Compounds and Use Thereof | PAM, AAAS, PAOX | CYP2D6 1856/4885CYP2C19 3345/4885ACLY 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.